Alder BioPharmaceuticals Announces Closing of $250M of 2.50% Convertible Senior Notes Due 2025 Post author:Sam Post published:February 1, 2018 Post category:BioPharma Alder intends to use the cash to fund the development and commercialization of eptinezumab. Source: BioSpace You Might Also Like Meet the Professor Who Was the First to Question Theranos' Research February 19, 2017 Are Life Science Companies Falling Behind Tech Companies? March 12, 2018 <b>Feldan Therapeutics</b> Announces Issuance Of First Patent For Its Peptide-Based Protein Delivery Technology, The Feldan Shuttle August 22, 2017
<b>Feldan Therapeutics</b> Announces Issuance Of First Patent For Its Peptide-Based Protein Delivery Technology, The Feldan Shuttle August 22, 2017